Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

European regulators give new medicines portal the go-ahead

EMA sets out plans for new online resource for patients, HCPs and academia 

EMAThe EMA has given the green light for the development of a new online resource for patients, consumers, carers, healthcare professionals and academia.

The European medicines web portal will be a multilingual website offering "free, reliable and unbiased information" on all medicines authorised in the EU.

This will be provided for a medicines entire lifecycle, from clinical trial information to adverse drug reaction reports, aiming to make it more visible.

Around three-quarters of the 508 million people in the European Union have access to the internet at home, many of whom use it for medical and health information.

The go-ahead for the new portal was agreed at a meeting last week of the EMA Management Board and setting out its vision for the new website the board said it would "provide a unique source of information on all medicines authorised in the EU".

"The website will help to position the EU medicines regulatory network as a core provider of free, unbiased, up-to-date, trustworthy, scientifically sound and validated online information on medicines, and will provide access to nationally authorised product information in a phased approach."

The information it provides will, the EMA said, comply with the HONcode standard for trustworthy health information and be accessible on both mobile devices and desktops.

Once live it will replace the EudraPharm online medicines database that the EMA developed in 2006 and incorporate both the European Database of Adverse Drug Reaction Reports and the EU Clinical Trials Register.

It will also swallow up the forthcoming clinical data website, which will be launched later this month to make clinical study reports externally available.

The web portal is a requirement of the 2010 pharmacovigilance legislation that came into effect in 2012 and marked the biggest changes to European regulations since the EMA was set up in 1995.

The EMA Management Board noted in a 'reflection paper' it signed off last week that the 2010 legislation also gave EU member states "the obligation to launch similar national medicines web portals".

The next steps for the European web portal will see the EMA collaborate with EU member states and the European Commission to develop a delivery plan and start scoping IT solutions it will need to support the project.

10th October 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....